CoChat

Risk of cardiovascular events and rofecoxib: cumulative meta-analysis

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Abstract

Background The cyclo-oxygenase 2 inhibitor rofecoxib was recently withdrawn because of cardiovascular adverse effects. An increased risk of myocardial infarction had been observed in 2000 in the Vioxx Gastrointestinal Outcomes Research study (VIGOR), but was attributed to cardioprotection of naproxen rather than a cardiotoxic effect of rofecoxib. We used standard and cumulative random-effects meta-analyses of randomised controlled trials and observational studies to establish whether robust evidence on the adverse effects of rofecoxib was available before September, 2004.Methods We searched bibliographic databases and relevant files of the US Food and Drug Administration. We included all randomised controlled trials in patients with chronic musculoskeletal disorders that compared rofecoxib with other non-steroidal anti-inflammatory drugs (NSAIDs) or placebo, and cohort and case-control studies of cardiovascular risk and naproxen. Myocardial infarction was the primary endpoint.Findings We identified 18 randomised controlled trials and 11 observational studies. By the end of 2000 (52 myocardial infarctions, 20742 patients) the relative risk from randomised controlled trials was 2.30 (95% CI 1.22-4.33, p=0.010), and 1 year later (64 events, 21432 patients) it was 2.24 (1.24-4.02, p=0.007). There was little evidence that the relative risk differed depending on the control group (placebo, non-naproxen NSAID, or naproxen; p=0.41) or trial duration (p=0.82). In observational studies, the cardioprotective effect of naproxen was small (combined estimate 0.86 [95% CI 0.75-0.99]) and could not have explained the findings of the VIGOR trial.Interpretation Our findings indicate that rofecoxib should have been withdrawn several years earlier. The reasons why manufacturer and drug licensing authorities did not continuously monitor and summarise the accumulating evidence need to be clarified.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(04)17514-4

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 48 references

Research works printed but not linked: 3

  1. Hawkey, 2000, Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo of the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial, Arthritis Rheum, 43, 370, 10.1002/1529-0131(200002)43:2<370::AID-ANR17>3.0.CO;2-D · doi:10.1002/1529-0131(200002)43:2<370::aid-anr17>3.0.co;2-d
  2. Geba, 2001, Onset of efficacy and patient assessment of clinical response in osteoarthritis (OA): comparison of rofecoxib to nabumetone, J Am Geriatr Soc, 49, S126
  3. Truitt, 2001, Results of a pivotal (Phase III) placebo and active comparator controlled efficacy trial of rofecoxib 12·5 and 25 mg in adult patients with rheumatoid arthritis (RA), Arthritis Rheum, 44, S369

Cited by

See all 846

Metadata

Authors
Jüni, P., Nartey, L., Reichenbach, S., Sterchi, R., Dieppe, P. A., & Egger, M.
Affiliations
  • University of Bern (CH)
  • University of Bristol (GB)
Corresponding author
Egger, Matthias
Venue
The Lancet
Publisher
Elsevier BV
Published
2004-12
Volume
364
Issue
9450
Pages
2021-2029
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2135393211
Cited by
846
References
47
Citations by year
2026: 11 · 2025: 16 · 2024: 15 · 2023: 8 · 2022: 18 · 2021: 14 · 2020: 26 · 2019: 15 · 2018: 13 · 2017: 14 · 2016: 30 · 2015: 32 · 2014: 35 · 2013: 37 · 2012: 50
FWCI
10.68
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • Explore Bristol Research (submittedVersion)
Funders
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
Keywords
rofecoxib, cardiovascular adverse events, myocardial infarction, COX-2 inhibitors, drug withdrawal, VIGOR trial, nonsteroidal anti-inflammatory drugs, pharmacovigilance
MeSH terms
Anti-Inflammatory Agents, Non-Steroidal, Arthritis, Rheumatoid, Cardiovascular Diseases, Humans, Lactones, Naproxen, Osteoarthritis, Risk Factors, Sulfones, Cohort Studies, Case-Control Studies, Randomized Controlled Trials as Topic, Cyclooxygenase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. https://app.cochat.ai/papers/10.1016/s0140-6736(04)17514-4
The paper
Jüni, P., Nartey, L., Reichenbach, S., Sterchi, R., Dieppe, P. A., & Egger, M. (2004). Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. The Lancet. https://doi.org/10.1016/s0140-6736(04)17514-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.